Objectives

After participating in this educational activity, attendees should be able to:

1. Understand how the pathophysiology of the disease leads to the clinical manifestations of HIT
2. Learn to calculate the 4T score and how to use it to determine the need for HIT testing
3. Learn the significance of the results of the HIT ELISA and SRA
4. Know what non-pharmacological interventions are necessary to manage and treat HIT.

Faculty:

C. Gabriela Macías, PharmD, MPH, (AQ-Cardiology)
Heart and Vascular Clinical Pharmacy Specialist - Baystate Medical Center
Co-Chair Anticoagulation Stewardship Initiative -Baystate Medical Center

Leslie M. Howard, M.D.
Assistant Program Director Hematology/Oncology - UMass/Baystate Medical Center
 

Faculty Disclosure

The design and content of Baystate Continuing Interprofessional Education ( CE ) activities support quality improvement in healthcare and provide fair and balanced views of therapeutic options.  All relevant financial relationships are mitigated prior to the educational activity.

None of the faculty and planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services consumed by or used on patients.

Gabriela Macia plans to discuss the off label use of the following medications for the acute treatment of heparin-induced thrombocytopenia (HIT):
-Bivalirudin
-Fondaparinux
-Rivaroxaban
-Apixaban

The use of these medications for the treatment of HIT is supported in primary literature and as well as guideline from the American Society of Hematology. 

Session date: 
Thursday, August 19, 2021 - 3:00pm to 4:00pm
Location: 
Webinar
Baystate Medical Center
759 Chestnut St.
Springfield, MA 01199
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 BCIPE Instructional Hours

Please login or register to take this course.